Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

ProBioGen AG. (3/8/18). "Press Release: ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program". Berlin.

Organisations Organisation ProBioGen AG
  Group Minapharm (Group)
  Organisation 2 Surface Oncology Inc.
Products Product contract manufacturing (biologicals)
  Product 2 antibody cancer drug
Person Person Schneider, Gabriele (ProBioGen 200309– Business Development)
     


Tumor Microenvironment Antibody, Parallel Cell Line Development till GMP Manufacturing


ProBioGen AG, a premier German service & technology provider for complex therapeutic glycoproteins announced signing the second antibody development project with Cambridge, MA-based Surface Oncology Inc., an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.

Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate. The advantage of this approach is the meticulous analysis of several candidates at the same time while strongly reducing time lines.

ProBioGen’s CBO, Dr Gabriele Schneider commented: “We have worked together with Surface Oncology very well for quite a while and this is now our second potential clinical antibody project together. We have established a seamless team working across our companies and we are very pleased to continue to expand this relationship with Surface Oncology”.


About ProBioGen AG www.probiogen.de

ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins. Combining both state-of-the-art development platforms, based on ProBioGen’s CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies, yields biologics with optimized properties.

Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.

All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994, is privately owned and located in Berlin, Germany.


Contact ProBioGen AG:

Dr Gabriele Schneider
Chief Business Officer
ProBioGen AG
Goethestr. 54
13086 Berlin, Germany
Phone: +49 (0)30 924 006-0
E-mail: cmo@probiogen.de
Website: www.probiogen.de

   
Record changed: 2018-03-22

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Minapharm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px




» top